× Industry Reports Services Press Release Contact us About us

North America Gene Editing Market Size By Technology (CRISPR/Cas9, Zinc Finger Nucleases (ZFNs), TALENs), By Application (Cell Line Engineering, Animal Genetic Engineering, Plant Genetic Engineering), By End-user (Biotech and Pharma Companies, Contract Research Organizations (CROs), Research Institutes), Industry Analysis Report, Country Outlook (U.S., Canada), Application Potential, Competitive Market Share & Forecast, 2020 - 2026
Published Date: November 2020 | Publisher: Graphical Research Report ID: GR1518 | Delivery : PDF  Request Free Sample

Report Content

Chapter 1   Methodology

1.1    Definition and forecast parameters

1.1.1    Definitions

1.1.2    Methodology and forecast parameters

1.2    Data sources

1.3    References & sources

1.3.1    Secondary

1.3.2    Primary

Chapter 2   Executive Summary

2.1    North America gene editing industry summary, 2015 - 2026

2.1.1    Country trends

2.1.2    Application trends

2.1.3    Technology trends

2.1.4    End-user trends

Chapter 3   Industry Insights

3.1    Industry segmentation

3.2    Industry outlook, 2015 - 2026

3.3    Major factor analysis

3.3.1    Drivers

3.3.1.1    Rising R&D expenditure and growth of biotechnology

3.3.1.2    Increased funding for genetic research in North America

3.3.1.3    Technology advancements in gene editing

3.3.1.4    Increasing demand for synthetic genes in North America

3.3.2    Restraints & challenges

3.3.2.1    Stringent government regulations

3.4    COVID-19 impact analysis

3.5    Porter’s analysis

3.6    Competitive review, 2019

3.7    PEST analysis

Chapter 4   North America Gene Editing Market Share, By Application

4.1    Key trends in North America gene editing, by application

4.2    Cell line engineering

4.2.1    Market estimates and forecast, by country, 2015 - 2026 (USD Million)

4.3    Animal genetic engineering

4.3.1    Market estimates and forecast, by country, 2015 - 2026 (USD Million)

4.4    Plant genetic engineering

4.4.1    Market estimates and forecast, by country, 2015 - 2026 (USD Million)

4.5    Others

4.5.1    Market estimates and forecast, by country, 2015 - 2026 (USD Million)

Chapter 5   North America Gene Editing Market Size, By Technology

5.1    Key trends in North America gene editing, by technology

5.2    CRISPR/Cas9

5.2.1    Market estimates and forecast, by country, 2015 - 2026 (USD Million)

5.3    Zinc Finger Nucleases (ZFNs)

5.3.1    Market estimates and forecast, by country, 2015 - 2026 (USD Million)

5.4    TALENs

5.4.1    Market estimates and forecast, by country, 2015 - 2026 (USD Million)

5.5    Others

5.5.1    Market estimates and forecast, by country, 2015 - 2026 (USD Million)

Chapter 6   North America Gene Editing Market Trends, By End-user

6.1    Key trends in North America gene editing, by end-user

6.2    Biotech and Pharma Companies

6.2.1    Market estimates and forecast, by country, 2015 - 2026 (USD Million)

6.3    Contract Research Organizations (CROs)

6.3.1    Market estimates and forecast, by country, 2015 - 2026 (USD Million)

6.4    Research Institutes

6.4.1    Market estimates and forecast, by country, 2015 - 2026 (USD Million)

Chapter 7   North America Gene Editing Market Growth, By Country

7.1    Key trends in North America gene editing, by country

7.2    U.S.

7.2.1    Market estimates and forecast, by application, 2015 - 2026 (USD Million)

7.2.2    Market estimates and forecast, by technology, 2015 - 2026 (USD Million)

7.2.3    Market estimates and forecast, by end-user, 2015 - 2026 (USD Million)

7.3    Canada

7.3.1    Market estimates and forecast, by application, 2015 - 2026 (USD Million)

7.3.2    Market estimates and forecast, by technology, 2015 - 2026 (USD Million)

7.3.3    Market estimates and forecast, by end-user, 2015 - 2026 (USD Million)

Chapter 8   Company Profiles

8.1    Addgene, Inc.

8.1.1    Business overview

8.1.2    Financial data

8.1.3    Product landscape

8.1.4    Strategic outlook

8.2    Agilent Technologies, Inc.

8.2.1    Business overview

8.2.2    Financial data

8.2.3    Product landscape

8.2.4    Strategic outlook

8.3    Allele Biotechnology and Pharmaceuticals Inc.

8.3.1    Business overview

8.3.2    Financial data

8.3.3    Product landscape

8.3.4    Strategic outlook

8.4    Applied StemCell

8.4.1    Business overview

8.4.2    Financial data

8.4.3    Product landscape

8.4.4    Strategic outlook

8.5    ATUM (DNA 2.0)

8.5.1    Business overview

8.5.2    Financial data

8.5.3    Product landscape

8.5.4    Strategic outlook

8.6    Bio-Rad Laboratories

8.6.1    Business overview

8.6.2    Financial data

8.6.3    Product landscape

8.6.4    Strategic outlook

8.7    Caribou Biosciences, Inc.

8.7.1    Business overview

8.7.2    Financial data

8.7.3    Product landscape

8.7.4    Strategic outlook

8.8    CRISPR Therapeutics

8.8.1    Business overview

8.8.2    Financial data

8.8.3    Product landscape

8.8.4    Strategic outlook

8.9    EMD Millipore (Merck KGaA)

8.9.1    Business overview

8.9.2    Financial data

8.9.3    Product landscape

8.9.4    Strategic outlook

8.10    GeneCopoeia

8.10.1    Business overview

8.10.2    Financial data

8.10.3    Product landscape

8.10.4    Strategic outlook

8.11    GenScript Corporation

8.11.1    Business overview

8.11.2    Financial data

8.11.3    Product landscape

8.11.4    Strategic outlook

8.12    Integrated DNA Technologies Inc.

8.12.1    Business overview

8.12.2    Financial data

8.12.3    Product landscape

8.12.4    Strategic outlook

8.13    Origene Technologies

8.13.1    Business overview

8.13.2    Financial data

8.13.3    Product landscape

8.13.4    Strategic outlook

8.14    Precision Biosciences

8.14.1    Business overview

8.14.2    Financial data

8.14.3    Product landscape

8.14.4    Strategic outlook

8.15    Sangamo Therapeutics

8.15.1    Business overview

8.15.2    Financial data

8.15.3    Product landscape

8.15.4    Strategic outlook

8.16    Takara Bio Inc.

8.16.1    Business overview

8.16.2    Financial data

8.16.3    Product landscape

8.16.4    Strategic outlook

8.17    Thermo Fisher Scientific

8.17.1    Business overview

8.17.2    Financial data

8.17.3    Product landscape

8.17.4    Strategic outlook

8.18    Beam Therapeutics

8.18.1    Business overview

8.18.2    Financial data

8.18.3    Product landscape

8.18.4    Strategic outlook

8.19    Bluebird bio, Inc.

8.19.1    Business overview

8.19.2    Financial data

8.19.3    Product landscape

8.19.4    Strategic outlook

8.20    Editas Medicine

8.20.1    Business overview

8.20.2    Financial data

8.20.3    Product landscape

8.20.4    Strategic outlook

8.21    Intellia Therapeutics

8.21.1    Business overview

8.21.2    Financial data

8.21.3    Product landscape

8.21.4    Strategic outlook
 


Premium Report

Have questions?
  • Inquire Before Buying
  • Why Choose us?

    • on-time delivery On-Time Delivery

      We commit to on-time delivery of reports to keep you ahead.

    • assured quality Assured Quility

      With a wide network of industry experts and trained in-house analysts, we assure best service quality.

    • Custom Research Service

      We offer research services to meet specific client requirements and provide them with actionable insights on target markets.

    • payment security Payment Security

      Our safe payment gateway gives you full control of your personal data, at all times.

    Connect with our sales team

     1-800-986-6917

     [email protected]